Neurocardiogenic syncope natural history
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Neurocardiogenic Syncope Microchapters |
|
Differentiating Neurocardiogenic Syncope From Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Neurocardiogenic syncope natural history On the Web |
|
American Roentgen Ray Society Images of Neurocardiogenic syncope natural history |
|
Risk calculators and risk factors for Neurocardiogenic syncope natural history |
Overview
Vasovagal syncope usually has an easily identified triggering event such as emotional stress, trauma, pain, the sight of blood, or prolonged standing. Syncope recurs in a few patients, while others just experience a single episode. Mortality associated with syncope is largely due to severity of the underlying disease rather than syncope per se.
Natural History
The natural history is extremely variable; some patients experience single episode while others have recurrent episodes. [1]
In an european study, 465 patients were evaluated for the early (1 month) and late (2 years) death rate and syncopal relapses of patients referred for syncope to 11 general hospitals emergency departments. The following results were found:[2]
- The death rate was higher (17% of all deaths) in the first month of observation
- Reoccurrence of the syncopal episode was low overall in both the short and the long term (0.3% and 0.8% in the first month and in the second year, respectively).
- Mortality was higher in patients having previous cardiovascular disease or in those displaying ECG abnormalities. Both of these two factors represent the main predictors of short- or long-term mortality on multivariate analysis
Prognosis
Vasovagal syncope appears to have a benign prognosis.[3] Patients recover completely within minutes to hours and have excellent prognosis as far as survival is concerned.[4] If syncope is symptomatic of an underlying condition, then the prognosis will reflect the course of the disorder and not the syncope itself,[5][6] and the patient should be stratified with respect to the risk of a cardiovascular event and/or sudden cardiac death and further evaluation is required. [7]
Risk of death and life-threatening events
Major risk factors for sudden cardiac death and overall mortality in patients are structural heart diseases[8][9] and primary electrical disturbances[10]. Hemodynaically important aortic stenosis [11] and increased age are also an important prognostic indicator.
Complication
The main danger of fainting fits or vasovagal syncope is the risk of injury by falling while unconscious. American Heart Association (AHA), North American Society of Pacing and Electrophysiology (NASPE, now Heart Rhythm Society, HRS) and European Society of Cardiology have published recommendations for driving in patients with syncope.[12][13][14]
The mortality in syncope patients depends on the underlying cause:[15]
- Cardiac causes (arrhythmias or cardiovascular disease) have a 20-30% mortality.
- Non-cardiac causes have 5-10% mortality.
However, a major drawback in determining the true mortality rate is that most individuals with transient loss of consciousness do not seek medical advice.
Related Chapters
Reference
- ↑ Alboni P, Brignole M, Degli Uberti EC (2007). "Is vasovagal syncope a disease?". Europace. 9 (2): 83–7. doi:10.1093/europace/eul179. PMID 17272328.
- ↑ Ungar A, Del Rosso A, Giada F, Bartoletti A, Furlan R, Quartieri F; et al. (2010). "Early and late outcome of treated patients referred for syncope to emergency department: the EGSYS 2 follow-up study". Eur Heart J. 31 (16): 2021–6. doi:10.1093/eurheartj/ehq017. PMID 20167743.
- ↑ Soteriades ES, Evans JC, Larson MG, Chen MH, Chen L, Benjamin EJ; et al. (2002). "Incidence and prognosis of syncope". N Engl J Med. 347 (12): 878–85. doi:10.1056/NEJMoa012407. PMID 12239256.
- ↑ Ruiz GA, Peralta A, Gonzalez-Zuelgaray J, Duce E (1995). "Evolution of patients with clinical neurocardiogenic (vasovagal) syncope not subjected to specific treatment". Am Heart J. 130 (2): 345–50. PMID 7631619.
- ↑ Eagle KA, Black HR, Cook EF, Goldman L (1985). "Evaluation of prognostic classifications for patients with syncope". Am. J. Med. 79 (4): 455–60. PMID 4050832. Retrieved 2012-05-17. Unknown parameter
|month=ignored (help) - ↑ Morady F, Shen E, Schwartz A, Hess D, Bhandari A, Sung RJ, Scheinman MM (1983). "Long-term follow-up of patients with recurrent unexplained syncope evaluated by electrophysiologic testing". J. Am. Coll. Cardiol. 2 (6): 1053–9. PMID 6630777. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ Veltmann C, Borggrefe M, Wolpert C, Schimpf R (2010). "Evaluation and management of syncope". Minerva Cardioangiol. 58 (6): 701–15. PMID 21135810.
- ↑ Martin TP, Hanusa BH, Kapoor WN (1997). "Risk stratification of patients with syncope". Ann Emerg Med. 29 (4): 459–66. PMID 9095005. Retrieved 2012-05-17. Unknown parameter
|month=ignored (help) - ↑ Olshansky B, Poole JE, Johnson G, Anderson J, Hellkamp AS, Packer D, Mark DB, Lee KL, Bardy GH (2008). "Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study". J. Am. Coll. Cardiol. 51 (13): 1277–82. doi:10.1016/j.jacc.2007.11.065. PMID 18371559. Retrieved 2012-05-17. Unknown parameter
|month=ignored (help) - ↑ Wehrens XH, Vos MA, Doevendans PA, Wellens HJ (2002). "Novel insights in the congenital long QT syndrome". Ann. Intern. Med. 137 (12): 981–92. PMID 12484714. Retrieved 2012-05-17. Unknown parameter
|month=ignored (help) - ↑ Kapoor WN, Karpf M, Wieand S, Peterson JR, Levey GS (1983). "A prospective evaluation and follow-up of patients with syncope". N. Engl. J. Med. 309 (4): 197–204. doi:10.1056/NEJM198307283090401. PMID 6866032. Retrieved 2012-05-17. Unknown parameter
|month=ignored (help) - ↑ Epstein AE, Miles WM, Benditt DG, Camm AJ, Darling EJ, Friedman PL, Garson A, Harvey JC, Kidwell GA, Klein GJ, Levine PA, Marchlinski FE, Prystowsky EN, Wilkoff BL (1996). "Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology". Circulation. 94 (5): 1147–66. PMID 8790068. Retrieved 2012-05-17. Unknown parameter
|month=ignored (help) - ↑ Epstein AE, Baessler CA, Curtis AB, Estes NA, Gersh BJ, Grubb B, Mitchell LB (2007). "Addendum to "Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology": public safety issues in patients with implantable defibrillators: a scientific statement from the American Heart Association and the Heart Rhythm Society". Circulation. 115 (9): 1170–6. doi:10.1161/CIRCULATIONAHA.106.180203. PMID 17287391. Retrieved 2012-05-17. Unknown parameter
|month=ignored (help) - ↑ Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, Deharo JC, Gajek J, Gjesdal K, Krahn A, Massin M, Pepi M, Pezawas T, Ruiz Granell R, Sarasin F, Ungar A, van Dijk JG, Walma EP, Wieling W (2009). "Guidelines for the diagnosis and management of syncope (version 2009)". Eur. Heart J. 30 (21): 2631–71. doi:10.1093/eurheartj/ehp298. PMC 3295536. PMID 19713422. Retrieved 2012-05-17. Unknown parameter
|month=ignored (help) - ↑ White CM, Tsikouris JP (2000). "A review of pathophysiology and therapy of patients with vasovagal syncope". Pharmacotherapy. 20 (2): 158–65. PMID 10678294.